phrykt

Veracyte, Inc. (VCYT): who owns it and who trades it

As of Nov 16, 2026, VCYT insiders reported 50 open-market sales worth $19.2M and no purchases in the last 12 months, with 94% of the sale value made under pre-set 10b5-1 plans. The largest seller was Marc Stapley (CEO), with $8.9M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Veracyte

From the latest filings

Overall: more selling than buying. Insiders and famous investors mostly sold. Funds was close to even.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns VCYT

367 funds and institutions reported VCYT shares worth $5.3B at the end of Q2 2026. Some shares are counted by more than one filer, or lent out and counted twice, so the total can pass 100%. The largest holder is BlackRock, Inc. with 16.9%.

Funds and institutions (13F) about 100%Everyone else 0%

10 largest owners, by share of the company

BlackRock, Inc.16.9%
FMR LLC (Fidelity)9.7%
Artisan Partners Limited Partnership6.9%
Vanguard Portfolio Management LLC5.9%
State Street Corp5.9%
Vanguard Capital Management LLC4.5%
Dimensional Fund Advisors LP3.5%
First Trust Advisors LP3.1%
ARK Investment Management LLC2.9%
Wellington Management Group LLP2.9%

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
BlackRock, Inc.13.49M16.90%$792M+2%
FMR LLC (Fidelity)7.70M9.65%$452M-1%
Artisan Partners Limited Partnership5.54M6.94%$325M+1%
Vanguard Portfolio Management LLC4.72M5.91%$277M+6%
State Street Corp4.70M5.89%$276M-7%
Vanguard Capital Management LLC3.59M4.50%$211M+2%
Dimensional Fund Advisors LP2.83M3.54%$166M-2%
First Trust Advisors LP2.51M3.14%$147M+18%
ARK Investment Management LLC2.30M2.88%$135M-25%
Wellington Management Group LLP2.27M2.85%$134M-11%
Geode Capital Management, LLC2.10M2.64%$124M+8%
Goldman Sachs Group Inc1.64M2.06%$96.5M+29%
Fuller & Thaler Asset Management, Inc.1.51M1.89%$88.7M+7%
William Blair Investment Management, LLC1.43M1.79%$84.1M+45%
GW&K Investment Management, LLC1.42M1.78%$83.2M-1%
Morgan Stanley1.19M1.49%$70M+49%
Bank of America Corp1.10M1.38%$64.7M-24%
Driehaus Capital Management LLC1.05M1.31%$61.4M–
Northern Trust Corp996,1541.25%$58.5M+7%
Charles Schwab Investment Management Inc939,9831.18%$55.2M+2%

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, VCYT insiders reported $0 of open-market purchases and $19.2M of sales. 94% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$0
0 trades, 0 people
Sales, 12 months
$19.2M
50 trades, 11 people
Sales under a 10b5-1 plan
94%
Share of sale value
Latest trade
Oct 27, 2026
Filed Oct 28, 2026

Purchases and sales by month

$8.2M$8.2MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Oct 27, 2026Karin EasthamDirectorSale plan14,850$50.00$743KForm 4
Oct 27, 2026Jens HolsteinDirectorSale plan7,500$50.00$375KForm 4
Oct 19, 2026Muna BhanjiDirectorSale plan1,864$43.70$81.5KForm 4
Sep 24, 2026Jens HolsteinDirectorSale plan7,500$47.00$352KForm 4
Sep 21, 2026John LeiteGlobal Chief Commercial Sale plan4,015$40.00$161KForm 4
Sep 14, 2026Jens HolsteinDirectorSale plan5,000$40.95$205KForm 4
Sep 4, 2026Phillip G. FebboChief Scientific & Med OSale plan10,405$42.89$446KForm 4
Sep 4, 2026Phillip G. FebboChief Scientific & Med OSale plan2,705$43.66$118KForm 4
Sep 4, 2026Rebecca ChambersCFOSale plan1,175$43.71$51.4KForm 4
Sep 4, 2026Rebecca ChambersCFOSale plan2,477$42.81$106KForm 4
Sep 4, 2026Annie McGuireVice presidentSale plan1,100$43.67$48KForm 4
Sep 4, 2026Annie McGuireVice presidentSale plan2,154$42.79$92.2KForm 4
Sep 1, 2026Muna BhanjiDirectorSale plan1,864$42.97$80.1KForm 4
Jun 18, 2026Karin EasthamDirectorSale plan3,200$52.78$169KForm 4
Jun 18, 2026Karin EasthamDirectorSale plan529$53.55$28.3KForm 4
Jun 4, 2026Annie McGuireVice presidentSale plan1,776$50.12$89KForm 4
Jun 4, 2026Annie McGuireVice presidentSale plan1,400$49.31$69KForm 4
Jun 4, 2026Rebecca ChambersCFOSale plan1,600$49.28$78.8KForm 4
Jun 4, 2026Rebecca ChambersCFOSale plan1,961$50.09$98.2KForm 4
Jun 4, 2026Marc StapleyCEOSale plan138,051$50.12$6.9MForm 4
Jun 4, 2026John LeiteGlobal Chief Commercial Sale plan13,975$50.07$700KForm 4
May 22, 2026Jonathan WygantVice presidentSale24,000$45.40$1.1MForm 4
May 20, 2026Robert S EpsteinDirectorSale plan10,000$44.01$440KForm 4
May 6, 2026Annie McGuireVice presidentSale plan5,102$38.05$194KForm 4
May 6, 2026Annie McGuireVice presidentSale plan5,102$40.00$204KForm 4
Mar 4, 2026Rebecca ChambersCFOSale plan13,941$36.33$506KForm 4
Mar 4, 2026Rebecca ChambersCFOSale plan4,400$35.55$156KForm 4
Mar 4, 2026Marc StapleyCEOSale plan26,279$36.28$953KForm 4
Mar 4, 2026Marc StapleyCEOSale plan19,244$35.56$684KForm 4
Mar 4, 2026John LeiteChief Commercial OfficerSale plan5,260$35.19$185KForm 4
Mar 4, 2026Annie McGuireVice presidentSale plan4,994$35.29$176KForm 4
Mar 4, 2026Annie McGuireVice presidentSale plan1,664$36.34$60.5KForm 4
Mar 2, 2026Phillip G. FebboChief Scientific & Med OSale plan13,425$36.16$485KForm 4
Dec 16, 2025Annie McGuireVice presidentSale plan10,639$43.13$459KForm 4
Dec 16, 2025Annie McGuireVice presidentSale plan100$43.68$4.4KForm 4
Dec 5, 2025Karin EasthamDirectorSale plan800$46.59$37.3KForm 4
Dec 5, 2025Karin EasthamDirectorSale plan12,808$45.84$587KForm 4
Dec 5, 2025Karin EasthamDirectorSale plan6,392$44.52$285KForm 4
Dec 4, 2025Annie McGuireVice presidentSale plan720$47.10$33.9KForm 4
Dec 4, 2025Annie McGuireVice presidentSale plan702$47.51$33.4KForm 4
Dec 4, 2025Rebecca ChambersCFOSale plan4,741$47.25$224KForm 4
Dec 4, 2025Rebecca ChambersCFOSale plan8,537$46.61$398KForm 4
Dec 4, 2025Marc StapleyCEOSale plan4,448$46.90$209KForm 4
Dec 4, 2025Marc StapleyCEOSale plan3,220$47.35$152KForm 4
Dec 4, 2025John LeiteChief Commercial OfficerSale plan1,278$47.51$60.7KForm 4
Nov 25, 2025John LeiteChief Commercial OfficerSale plan2,808$50.00$140KForm 4
Nov 25, 2025Evan/ Fa JonesDirectorSale plan1,106$50.25$55.6KForm 4
Nov 20, 2025Jens HolsteinDirectorSale plan7,049$42.48$299KForm 4
Nov 20, 2025Jens HolsteinDirectorSale plan1,491$40.95$61.1KForm 4
Nov 20, 2025Jens HolsteinDirectorSale plan1,460$43.21$63.1KForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Marc StapleyChief Executive Officer, Director–$8.9MJun 4, 2026
Karin EasthamDirector–$1.8MOct 27, 2026
Rebecca ChambersChief Financial Officer–$1.6MSep 4, 2026
Annie McGuireSVP, General Counsel–$1.5MSep 4, 2026
Jens HolsteinDirector–$1.4MOct 27, 2026
John LeiteChief Commercial Officer-CLIA–$1.2MSep 21, 2026
Jonathan WygantVP, Chief Accounting Officer–$1.1MMay 22, 2026
Phillip G. FebboChief Scientific & Med Officer–$1MSep 4, 2026
Robert S EpsteinDirector–$440KMay 20, 2026
Muna BhanjiDirector–$162KOct 19, 2026
Evan/ Fa JonesDirector–$55.6KNov 25, 2025
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

VCYT short interest

High short interest. 11.8% of VCYT shares are sold short: about 1 share in 8. Over the last 12 reports the number of shares short went up 11%.

As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.

0%5%10%15%20%+

As of Oct 30, 2026, 9.56M VCYT shares were sold short, 11.8% of the shares outstanding, down 2.7% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 8.2 trading days (days to cover).

Shares short, % of all shares

11.8%May 15Oct 3013.3%

Days to cover

8.2May 15Oct 309.2

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20269.56M11.85%-3%1.16M8.2
Oct 15, 20269.82M12.22%-4%1.16M8.5
Sep 30, 202610.18M12.66%+21%1.73M5.9
Sep 15, 20268.40M10.45%+4%1.08M7.8
Aug 31, 20268.08M10.05%+19%1.38M5.8
Aug 14, 20266.79M8.45%-1%1.21M5.6
Jul 31, 20266.86M8.53%+3%1.43M4.8
Jul 15, 20266.67M8.36%-1%988,6546.8
Jun 30, 20266.72M8.42%-21%1.77M3.8
Jun 15, 20268.49M10.64%+15%1.31M6.5
May 29, 20267.35M9.21%-14%1.14M6.5
May 15, 20268.59M10.77%+25%1.19M7.2

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Members of Congress who traded VCYT

Since Nov 17, 2024, 1 member of Congress reported 2 purchases and 1 sale of VCYT. The latest was a purchase by Gilbert Ray Cisneros, Jr. on Mar 3, 2026, reported Apr 7, 2026.

Purchases 2Sales 1

Reported trades

Trade dateMemberTypeAmountOwnerReportedSource
Mar 3, 2026Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfApr 7, 2026Report
Nov 12, 2025Gilbert Ray Cisneros, Jr. (D-CA)Partial sale$1K–$15KSelfDec 15, 2025Report
Jun 16, 2025Gilbert Ray Cisneros, Jr. (D-CA)Purchase$1K–$15KSelfJul 10, 2025Report

Source: Periodic Transaction Reports filed with the Clerk of the House and the Secretary of the Senate under the STOCK Act. Members report each trade within 45 days, as a dollar range, not an exact amount. Trades by a spouse or dependent child are included and marked. Paper filings (scanned images) are not included, and Senate reports are shown for current senators only. Links to Senate reports open the Senate’s own site, which shows its terms first and can only be reached from the United States. How these reports work

Veracyte company events

Veracyte filed 8 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 4, 2026.

  1. Nov 4, 2026AnnouncementThe Company announced the commencement of a share repurchase program previously authorized by the Board of Directors of the Company, pursuant to which the Company may repurchase up to $100.0 million of its outstanding common stock during the one-year period beginning on the date of the public… Filing
  2. Sep 14, 2026DealVeracyte completed its acquisition of Convergent pursuant to the terms of the Merger Agreement. Filing
  3. Jul 30, 2026ResultsReleased financial results. Filing
  4. Jun 11, 2026LeadershipAs further described in Item 5.07 to this Current Report on Form 8-K (this “Report”), on June 10, 2026, at the 2026 Annual Meeting of Stockholders of Veracyte, Inc., the Company’s stockholders approved an amendment to the Company’s 2023 Equity Incentive Plan to increase the number of shares of the… Filing
  5. May 5, 2026ResultsReleased financial results. Filing
  6. Mar 16, 2026LeadershipVeracyte, Inc. announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026. Filing
  7. Feb 25, 2026ResultsReleased financial results. Filing
  8. Jan 12, 2026ResultsReleased financial results. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Veracyte financials

Famous investors that hold VCYT

5 of the 50 well-known investors we track reported holding VCYT in their latest 13F filing. The largest position is Cathie Wood's, worth $136M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Cathie Wood · ARK Investment ManagementQ3 20262.96M$136M0.8%+29%
Ken Fisher · Fisher Asset ManagementQ3 2026682,711$31.4M0.0%-3%
Ken Griffin · Citadel AdvisorsQ3 202693,410$4.3M0.0%New
Ray Dalio · Bridgewater AssociatesQ3 202655,339$2.5M0.0%-5%
Israel Englander · Millennium ManagementQ3 202610,446$481K0.0%-85%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 4 filings named VCYT in the last 120 days.

FiledHolderFormStake
Nov 12, 2026Artisan Partners Asset Management Inc.13G/A2.9%
Nov 12, 2026Artisan Partners Asset Management Inc.13G/A2.9%
Nov 5, 2026FMR LLC13G/A7.7%
Nov 5, 2026FMR LLC13G/A7.7%

Questions about Veracyte, Inc. (VCYT) stock

Who owns the most VCYT stock?

The largest reported owner of Veracyte, Inc. (VCYT) is BlackRock, Inc., with 16.9% of the company. In total, 367 funds and institutions reported holding VCYT at the end of Q2 2026, together about 100% of the shares. See the largest owners.

Are VCYT insiders buying or selling?

In the last 12 months, VCYT insiders reported no open-market purchases and 50 sales worth $19.2M. The latest trade was on Oct 27, 2026. See every trade.

What is the short interest in VCYT?

As of Oct 30, 2026, 9.56M VCYT shares were sold short, 11.8% of the shares outstanding, down 2.7% from the report before. At the average daily volume of 1.16M shares, buying them all back would take about 8.2 trading days (days to cover). See the history.

Have members of Congress traded VCYT?

Yes. 1 member of Congress reported 2 purchases and 1 sale of VCYT since Nov 17, 2024. The latest was reported on Apr 7, 2026. See the trades.

Which famous investors hold VCYT?

5 of the 50 well-known investors we track reported VCYT in their latest 13F filing, including Cathie Wood, Ken Fisher, Ken Griffin. The largest position is worth $136M. See all holders.

Executive pay

Veracyte's chief executive was paid a total of $7.4M for the year ended Dec 31, 2025. In the last 12 months, Veracyte's executives and directors bought no stock on the open market and sold $19.2M.

Chief executive, total pay$7.4MYear ended Dec 31, 2025. Salary, bonus and the value of stock and option awards when granted.
Pay "actually paid"$9.6MThe same year, with stock awards valued at what they were worth as they vested or at year end.
Other top executives, average$2.8MThe other officers named in the proxy statement.

From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.